Advertisement

Topics

Latest "Reddy Laboratories" News Stories

06:43 EST 17th December 2017 | BioPortfolio

Here are the most relevant search results for "Reddy Laboratories" found in our extensive news archives from over 250 global news sources.

More Information about Reddy Laboratories on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Reddy Laboratories for you to read. Along with our medical data and news we also list Reddy Laboratories Clinical Trials, which are updated daily. BioPortfolio also has a large database of Reddy Laboratories Companies for you to search.

Showing "Reddy Laboratories" News Articles 1–25 of 2,400+

Extremely Relevant

Dr. Reddy's Laboratories Ltd (RDY) Set to Announce Earnings on Tuesday

Dr. Reddy's Laboratories Ltd will be releasing its earnings data after the market closes on Tuesday, October 31st. Shares of Dr. Reddy's Laboratories Ltd traded down 0.28% during midday trading on Tuesday, reaching $36.15.


Dr. Reddy's Out-Licenses Plaque Psoriasis Drug to Encore Dermatology

NewsDr. Reddy's Laboratories announces the out-licensing of DFD-06 to Encore Dermatology. Under the terms of the agreement, Encore will be responsible for the commercialization of DFD-06 in the United States.

Dr. Reddy's Launches Generic Version of Genzyme Corp.'s Renvela in U.S.

NewsDr. Reddy's Laboratories announces the launch of sevelamer carbonate tablets in the U.S. market. It is a therapeutic equivalent generic version of Genzyme Corporation's Renvela.


Dr. Reddy's Laboratories Announces the Launch of Generic Azacitidine for Injection in the ...

DR. REDDY'S LABORATORIES LTD.INVESTOR RELATIONSSAUNAK SAVLAsaunaks@drreddys.com(Ph: +91-40-49002135)orMEDIA RELATIONSCALVIN PRINTERcalvinprinter@drreddys.com(Ph: +91-40- 49002121) Read more...

Dr. Reddy's Laboratories Announces Out-Licensing of DFD-06 to Encore Dermatology

NewsThe drug is intended to be used for treatment of moderate to severe plaque psoriasis.

Pomerantz LLP: SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Ltd. - RDY

NEW YORK, NY / ACCESSWIRE / September 11, 2017 / Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Ltd. ("Dr. Reddy's" or the "Company") (NYSE: RDY). Such inv...

IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Dr. Reddy's Laboratories Limited and Reminds Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / September 19, 2017 / Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Dr. Reddy's Laboratories Limited ('Dr. Reddy's' or the 'Compan...

IMPORTANT EQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Dr. Reddy's Laboratories Limited and Reminds Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / September 27, 2017 / Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Dr. Reddy's Laboratories Limited ("Dr. Reddy's" or the "Compan...

Dr. Reddy’s Laboratories Announces the Launch of Sevelamer Carbonate Tablets in the U.S. Market

HYDERABAD, India & PRINCETON, N.J.–(BUSINESS WIRE)–Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that it has launched Sevelamer Carbonate Tablets, 800 mg, a therapeutic equivalent generic version of Renvela® (sevelamer carbonate) Tablets, approved by the U.S. … Continue reading → Cet article Dr. Reddy’s Laboratories Annou...

DEADLINE ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Dr. Reddy's Laboratories Limited and Reminds Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / October 10, 2017 / Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Dr. Reddy's Laboratories Limited ("Dr. Reddy's" or the "Company"...

DEADLINE APPROACHING: Lundin Law PC Announces Securities Class Action Lawsuit against Dr. Reddy's Laboratories Limited and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / October 12, 2017 / Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Dr. Reddy's Laboratories Limited ("Dr. Reddy's" or the "Company"...

DEADLINE REMINDER: Lundin Law PC Announces Securities Class Action Lawsuit against Dr. Reddy's Laboratories Limited and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / October 18, 2017 / Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Dr. Reddy's Laboratories Limited ("Dr. Reddy's" or the "Company"...

INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Dr. Reddy's Laboratories Limited and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / September 8, 2017 / Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against Dr. Reddy's Laboratories Limited ("Dr. Reddy's" o...

EQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Dr. Reddy's Laboratories Limited and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / September 14, 2017 / Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Dr. Reddy's Laboratories Limited ("Dr. Reddy's" or the "Compan...

UPCOMING DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit against Dr. Reddy's Laboratories Limited and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / October 16, 2017 / Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Dr. Reddy's Laboratories Limited ("Dr. Reddy's" or the "Company"...

INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Dr. Reddy's Laboratories Limited and Reminds Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / September 29, 2017 / Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Dr. Reddy's Laboratories Limited ("Dr. Reddy's" or the "Compan...

Dr. Reddy's Laboratories Ltd (RDY) Upgraded to "Overweight" at Morgan Stanley

A number of other equities research analysts also recently weighed in on RDY. BidaskClub downgraded Dr. Reddy's Laboratories from a hold rating to a sell rating in a research report on Monday, July 31st.

SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Dr. Reddy's Laboratories Limited and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / September 12, 2017 / Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against Dr. Reddy's Laboratories Limited ("Dr. Reddy's" ...

SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Dr. Reddy's Laboratories Limited and Reminds Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / October 3, 2017 / Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Dr. Reddy's Laboratories Limited ("Dr. Reddy's" or the "Company")...

Dr. Reddy’s and CHD Sign License Deal to Commercialize Surgical Infection Gel

NewsDr. Reddy’s and CHD Bioscience announce global license and commercialization agreement for Phase III clinical trial candidate for mitigation of surgical site infections.

IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Dr. Reddy's Laboratories Limited and Reminds Investors with Losses to Contact the Firm

IRVINE, CA / ACCESSWIRE / September 20, 2017 / Khang & Khang LLP (the "Firm") announces a securities class action lawsuit against Dr. Reddy's Laboratories Limited ("Dr. Reddy's" or the "Company") (...

IMPORTANT EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Dr. Reddy's Laboratories Limited and Reminds Investors with Losses to Contact the Firm

IRVINE, CA / ACCESSWIRE / September 28, 2017 / Khang & Khang LLP (the "Firm") announces a securities class action lawsuit against Dr. Reddy's Laboratories Limited ("Dr. Reddy's" or the "Company") (...

SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Dr. Reddy's Laboratories Limited and Encourages Investors with Losses to Contact the Firm

IRVINE, CA / ACCESSWIRE / September 11, 2017 / Khang & Khang LLP (the 'Firm') announces the filing of a securities class action lawsuit against Dr. Reddy's Laboratories Limited ('Dr. Reddy's' or th...

APPROACHING DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Dr. Reddy's Laboratories Limited and Reminds Investors with Losses to Contact the Firm

IRVINE, CA / ACCESSWIRE / October 11, 2017 / Khang & Khang LLP (the 'Firm') announces a securities class action lawsuit against Dr. Reddy's Laboratories Limited ('Dr. Reddy's' or the 'Company') (NY...

INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Dr. Reddy's Laboratories Limited and Encourages Investors with Losses to Contact the Firm

IRVINE, CA / ACCESSWIRE / September 13, 2017 / Khang & Khang LLP (the "Firm") announces the filing of a securities class action lawsuit against Dr. Reddy's Laboratories Limited ("Dr. Reddy's" or th...


Quick Search
Advertisement
 

News Quicklinks